StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report issued on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 1.4 %
Shares of NASDAQ:AKTX opened at $2.24 on Thursday. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $4.40. The company’s fifty day moving average price is $3.23 and its 200 day moving average price is $2.71.
Akari Therapeutics Company Profile
Further Reading
- Five stocks we like better than Akari Therapeutics
- Ride Out The Recession With These Dividend Kings
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Best Stocks Under $10.00
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- The Most Important Warren Buffett Stock for Investors: His Own
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.